Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 423713, 18 pages
http://dx.doi.org/10.1155/2013/423713
Review Article

Can Medical Herbs Stimulate Regeneration or Neuroprotection and Treat Neuropathic Pain in Chemotherapy-Induced Peripheral Neuropathy?

1HanseMerkur Center for Traditional Chinese Medicine at the University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
2ICBAS, University of Porto, Rua de Jorge Viterbo Ferreira No. 228, 4050-313 Porto, Portugal
3Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy
4Hubertus Wald Tumorzentrum, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
5Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany

Received 30 April 2013; Accepted 5 June 2013

Academic Editor: Yoshiharu Motoo

Copyright © 2013 Sven Schröder et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Wilkes, “Peripheral neuropathy related to chemotherapy,” Seminars in Oncology Nursing, vol. 23, no. 3, pp. 162–173, 2007. View at Publisher · View at Google Scholar
  2. R. B. Lipton, S. C. Apfel, J. P. Dutcher et al., “Taxol produces a predominantly sensory neuropathy,” Neurology, vol. 39, no. 3, pp. 368–373, 1989. View at Google Scholar · View at Scopus
  3. J. M. A. van Gerven, J. W. B. Moll, M. J. van den Bent et al., “Paclitaxel (Taxol) induces cumulative mild neurotoxicity,” European Journal of Cancer A, vol. 30, no. 8, pp. 1074–1077, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Visovsky, M. Collins, L. Abbott, J. Aschenbrenner, and C. Hart, “Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy,” Clinical Journal of Oncology Nursing, vol. 11, no. 6, pp. 901–913, 2007. View at Google Scholar · View at Scopus
  5. J. W. Hay, “Quality of life effects of chemotherapy-induced neuropathy in ovarian cancer,” Proceedings of the American Society of Clinical Oncology, vol. 21, abstract 886, p. 222a, 2002. View at Google Scholar
  6. R. B. Lipton, S. C. Apfel, J. P. Dutcher et al., “Taxol produces a predominantly sensory neuropathy,” Neurology, vol. 39, no. 3, pp. 368–373, 1989. View at Google Scholar · View at Scopus
  7. F. H. Hausheer, R. L. Schilsky, S. Bain, E. J. Berghorn, and F. Lieberman, “Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy,” Seminars in Oncology, vol. 33, no. 1, pp. 15–49, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. M. Corse and R. W. Kunel, “Peripheral neuropathy,” in Principles of Ambulatory Medicine, L. R. Barker, J. R. Burton, and P. D. Zieve, Eds., pp. 1296–1314, Williams & Wilkins, Baltimore, Md, USA, 5th edition, 1999. View at Google Scholar
  9. Oxaliplatin Prescribing Information. Drugs.com. Hospira Worldwide, 2013, http://www.drugs.com/pro/oxaliplatin.html.
  10. F. H. Hausheer, R. L. Schilsky, S. Bain, E. J. Berghorn, and F. Lieberman, “Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy,” Seminars in Oncology, vol. 33, no. 1, pp. 15–49, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Chaudhry, M. Chaudhry, T. O. Crawford, E. Simmons-O'Brien, and J. W. Griffin, “Toxic neuropathy in patients with pre-existing neuropathy,” Neurology, vol. 60, no. 2, pp. 337–340, 2003. View at Google Scholar · View at Scopus
  12. S. Mielke, K. Mross, T. A. Gerds et al., “Comparative neurotoxicity of weekly non-break paditaxel infusions over 1 versus 3 h,” Anti-Cancer Drugs, vol. 14, no. 10, pp. 785–792, 2003. View at Google Scholar · View at Scopus
  13. A. de Gramont, C. Boni, M. Navaro et al., “Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a medican follow-up of 4 years,” Journal of Clinical Oncology, vol. 23, p. 16, 2005. View at Google Scholar
  14. A. Grothey, “Clinical management of oxaliplatin-associated neurotoxicity,” Clinical Colorectal Cancer, vol. 5, no. 1, pp. S38–S46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. R. W. Kuncl and E. B. George, “Toxic neuropathies and myopathies,” Current Opinion in Neurology, vol. 6, no. 5, pp. 695–704, 1993. View at Google Scholar · View at Scopus
  16. S. Quasthoff and H. P. Hartung, “Chemotherapy-induced peripheral neuropathy,” Journal of Neurology, vol. 249, no. 1, pp. 9–17, 2002. View at Google Scholar · View at Scopus
  17. R. W. Gregg, J. M. Molepo, V. J. A. Monpetit et al., “Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity,” Journal of Clinical Oncology, vol. 10, no. 5, pp. 795–803, 1992. View at Google Scholar · View at Scopus
  18. J. S. Gill and A. J. Windebank, “Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle,” The Journal of Clinical Investigation, vol. 101, no. 12, pp. 2842–2850, 1998. View at Google Scholar · View at Scopus
  19. M. S. Yoon, Z. Katsarava, M. Obermann et al., “Erythropoietin overrides the triggering effect of DNA platination products in a mouse model of Cisplatin-induced neuropathy,” BMC Neuroscience, vol. 10, article 77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. E. K. Joseph and J. D. Levine, “Mitochondrial electron transport in models of neuropathic and inflammatory pain,” Pain, vol. 121, no. 1-2, pp. 105–114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. E. K. Joseph and J. D. Levine, “Comparison of oxaliplatin- and Cisplatin-induced painful peripheral neuropathy in the rat,” The Journal of Pain, vol. 10, no. 5, pp. 534–541, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. E. K. Joseph, X. Chen, O. Bogen, and J. D. Levine, “Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy,” The Journal of Pain, vol. 9, no. 5, pp. 463–472, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Cavaletti, G. Tredici, M. Braga, and S. Tazzari, “Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol,” Experimental Neurology, vol. 133, no. 1, pp. 64–72, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. C. M. Peters, J. M. Jimenez-Andrade, M. A. Kuskowski, J. R. Ghilardi, and P. W. Mantyh, “An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat,” Brain Research, vol. 1168, no. 1, pp. 46–59, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. O. A. Shemesh and M. E. Spira, “Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy,” Acta Neuropathologica, vol. 119, no. 2, pp. 235–248, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. L. H. Weimer, “Medication-induced peripheral neuropathy,” Current Neurology and Neuroscience Reports, vol. 3, no. 1, pp. 86–92, 2003. View at Google Scholar · View at Scopus
  27. K. D. Tanner, J. D. Levine, and K. S. Topp, “Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat,” Journal of Comparative Neurology, vol. 395, pp. 481–492, 1998. View at Google Scholar
  28. K. S. Topp, K. D. Tanner, and J. D. Levine, “Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat,” Journal of Comparative Neurology, vol. 424, no. 4, pp. 563–576, 2000. View at Google Scholar · View at Scopus
  29. Z. Sahenk, S. T. Brady, and J. R. Mendell, “Studies on the pathogenesis of vincristine-induced neuropathy,” Muscle and Nerve, vol. 10, no. 1, pp. 80–84, 1987. View at Google Scholar · View at Scopus
  30. S. Lobert, B. Vulevic, and J.-J. Correia, “Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine,” Biochemistry, vol. 35, no. 21, pp. 6806–6814, 1996. View at Publisher · View at Google Scholar · View at Scopus
  31. A. A. Argyriou, P. Marmiroli, G. Cavaletti, and H. P. Kalofonos, “Epothilone-induced peripheral neuropathy: a review of current knowledge,” Journal of Pain and Symptom Management, vol. 42, no. 6, pp. 931–940, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. R. J. Kowalski, P. Giannakakou, and E. Hamel, “Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol),” The Journal of Biological Chemistry, vol. 272, no. 4, pp. 2534–2541, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. K. H. Altmann, M. Wartmann, and T. O'Reilly, “Epothilones and related structures—a new class of microtubule inhibitors with potent in vivo antitumor activity,” Biochimica et Biophysica Acta, vol. 1470, no. 3, pp. M79–M91, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. A. A. Argyriou, G. Iconomou, and H. P. Kalofonos, “Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature,” Blood, vol. 112, no. 5, pp. 1593–1599, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Cavaletti and E. Nobile-Orazio, “Bortezomib-induced peripheral neurotoxicity: still far from a painless gain,” Haematologica, vol. 92, no. 10, pp. 1308–1310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Cavaletti, A. Gilardini, A. Canta et al., “Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat,” Experimental Neurology, vol. 204, no. 1, pp. 317–325, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Casafont, M. T. Berciano, and M. Lafarga, “Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons,” Neurotoxicity Research, vol. 17, no. 2, pp. 167–178, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. T. H. Landowski, C. J. Megli, K. D. Nullmeyer, R. M. Lynch, and R. T. Dorr, “Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/Bortezomib) cytotoxicity in myeloma cell lines,” Cancer Research, vol. 65, no. 9, pp. 3828–3836, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Montagut, A. Rovira, and J. Albanell, “The proteasome: a novel target for anticancer therapy,” Clinical and Translational Oncology, vol. 8, no. 5, pp. 313–317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. C. H. Chung, J. Aulino, N. J. Muldowney et al., “Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma,” Annals of Oncology, vol. 21, no. 4, pp. 864–870, 2010. View at Publisher · View at Google Scholar
  41. J. P. Cata, H. R. Weng, A. W. Burton, H. Villareal, S. Giralt, and P. M. Dougherty, “Quantitative sensory findings in patients with bortezomib-induced pain,” The Journal of Pain, vol. 8, no. 4, pp. 296–306, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. E. R. Lepper, N. F. Smith, M. C. Cox, C. D. Scripture, and W. D. Figg, “Thalidomide metabolism and hydrolysis: mechanisms and implications,” Current Drug Metabolism, vol. 7, no. 6, pp. 677–685, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Cavaletti and P. Marmiroli, “Chemotherapy-induced peripheral neurotoxicity,” Nature Reviews Neurology, vol. 6, no. 12, pp. 657–666, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. D. H. Moore, J. Donnelly, W. P. McGuire et al., “Limited access trial using amifostine for protection against Cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group,” Journal of Clinical Oncology, vol. 21, no. 22, pp. 4207–4213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Masuda, S. Negoro, F. Hausheer et al., “Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer,” Cancer Chemotherapy and Pharmacology, vol. 67, no. 3, pp. 533–542, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. D. R. Gandara, V. J. Wiebe, E. A. Perez, R. W. Makuch, and M. W. DeGregorio, “Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate,” Critical Reviews in Oncology/Hematology, vol. 10, no. 4, pp. 353–365, 1990. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Tredici, M. Braga, G. Nicolini et al., “Effect of recombinant human nerve growth factor on Cisplatin neurotoxicity in rats,” Experimental Neurology, vol. 159, no. 2, pp. 551–558, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Aloe, L. Manni, F. Properzi, S. de Santis, and M. Fiore, “Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by Cisplatin: behavioral, structural and biochemical analysis,” Autonomic Neuroscience, vol. 86, no. 1-2, pp. 84–93, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. W. Q. Gao, N. Dybdal, N. Shinsky et al., “Neurotrophin-3 reverses experimental Cisplatin-induced peripheral sensory neuropathy,” Annals of Neurology, vol. 38, no. 1, pp. 30–37, 1995. View at Publisher · View at Google Scholar · View at Scopus
  50. I. D. Davis, L. Kiers, L. MacGregor et al., “A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, Emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy,” Clinical Cancer Research, vol. 11, no. 5, pp. 1890–1898, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. I. Cervellini, E. Bello, R. Frapolli et al., “The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13,762 adenocarcinoma-bearing rats,” Neurotoxicity Research, vol. 18, no. 2, pp. 151–160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Bianchi, A. Gilardini, V. Rodriguez-Menendez et al., “Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth,” European Journal of Cancer, vol. 43, no. 4, pp. 710–717, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Dicato and L. Plawny, “Erythropoietin in cancer patients: pros and cons,” Current Opinion in Oncology, vol. 22, no. 4, pp. 307–311, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Cascinu, L. Cordella, E. del Ferro, M. Fronzoni, and G. Catalano, “Neuroprotective effect of reduced glutathione on Cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo- controlled trial,” Journal of Clinical Oncology, vol. 13, no. 1, pp. 26–32, 1995. View at Google Scholar · View at Scopus
  55. S. Cascinu, V. Catalano, L. Cordella et al., “Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial,” Journal of Clinical Oncology, vol. 20, no. 16, pp. 3478–3483, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Bove, M. Picardo, V. Maresca, B. Jandolo, and A. Pace, “A pilot study on the relation between Cisplatin neuropathy and vitamin E,” Journal of Experimental and Clinical Cancer Research, vol. 20, no. 2, pp. 277–280, 2001. View at Google Scholar · View at Scopus
  57. A. A. Argyriou, E. Chroni, A. Koutras et al., “Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial,” Neurology, vol. 64, no. 1, pp. 26–31, 2005. View at Google Scholar · View at Scopus
  58. A. A. Argyriou, E. Chroni, A. Koutras et al., “Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation,” Journal of Pain and Symptom Management, vol. 32, no. 3, pp. 237–244, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Pace, D. Giannarelli, E. Galiè et al., “Vitamin E neuroprotection for Cisplatin neuropathy: a randomized, placebo-controlled trial,” Neurology, vol. 74, no. 9, pp. 762–766, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Pisano, G. Pratesi, D. Laccabue et al., “Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine,” Clinical Cancer Research, vol. 9, no. 15, pp. 5756–5767, 2003. View at Google Scholar · View at Scopus
  61. W. Boehmerle, K. Zhang, M. Sivula et al., “Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 26, pp. 11103–11108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. V. A. Carozzi, A. Chiorazzi, A. Canta et al., “Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat,” Neurotoxicity Research, vol. 17, no. 4, pp. 380–391, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. P. C. Kurniali, L. G. Luo, and A. B. Weitberg, “Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients,” Oncology, vol. 24, no. 3, pp. 289–292, 2010. View at Google Scholar · View at Scopus
  64. G. Cavaletti and P. Marmiroli, “The role of growth factors in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity,” Current Drug Safety, vol. 1, no. 1, pp. 35–42, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Albers, V. Chaudhry, G. Cavaletti, and R. Donehower, “Interventions for preventing neuropathy caused by Cisplatin and related compounds,” Cochrane Database of Systematic Reviews, vol. 1, Article ID CD005228, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Wolf, D. Barton, L. Kottschade, A. Grothey, and C. Loprinzi, “Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies,” European Journal of Cancer, vol. 44, no. 11, pp. 1507–1515, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. G. Kannarkat, E. E. Lasher, and D. Schiff, “Neurologic complications of chemotherapy agents,” Current Opinion in Neurology, vol. 20, no. 6, pp. 719–725, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Muthuraman and N. Singh, “Attenuating effect of Acorus calamus extract in chronic constriction injury induced neuropathic pain in rats: an evidence of anti-oxidative, anti-inflammatory, neuroprotective and calcium inhibitory effects,” BMC Complementary and Alternative Medicine, vol. 11, article 24, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Muthuraman, N. Singh, and A. S. Jaggi, “Effect of hydroalcoholic extract of Acorus calamus on tibial and sural nerve transection-induced painful neuropathy in rats,” Journal of Natural Medicines, vol. 65, no. 2, pp. 282–292, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Muthuraman and N. Singh, “Attenuating effect of hydroalcoholic extract of Acorus calamus in vincristine-induced painful neuropathy in rats,” Journal of Natural Medicines, vol. 65, no. 3-4, pp. 480–487, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. E. J. Rahn, A. M. Zvonok, G. A. Thakur, A. D. Khanolkar, A. Makriyannis, and A. G. Hohmann, “Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 327, no. 2, pp. 584–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. R. J. Ellis, W. Toperoff, F. Vaida et al., “Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial,” Neuropsychopharmacology, vol. 34, no. 3, pp. 672–680, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Karst, K. Salim, S. Burstein, I. Conrad, L. Hoy, and U. Schneider, “Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial,” Journal of the American Medical Association, vol. 290, no. 13, pp. 1757–1762, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. M. A. Ware, T. Wang, S. Shapiro et al., “Smoked cannabis for chronic neuropathic pain: a randomized controlled trial,” Canadian Medical Association Journal, vol. 182, no. 14, pp. E694–E701, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. D. J. Rog, T. J. Nurmikko, T. Friede, and C. A. Young, “Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis,” Neurology, vol. 65, no. 6, pp. 812–819, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. D. R. Blake, P. Robson, M. Ho, R. W. Jubb, and C. S. McCabe, “Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis,” Rheumatology, vol. 45, no. 1, pp. 50–52, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. J. S. Berman, C. Symonds, and R. Birch, “Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial,” Pain, vol. 112, no. 3, pp. 299–306, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. B. Wilsey, T. Marcotte, A. Tsodikov et al., “A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain,” The Journal of Pain, vol. 9, no. 6, pp. 506–521, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. D. I. Abrams, C. A. Jay, S. B. Shade et al., “Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial,” Neurology, vol. 68, no. 7, pp. 515–521, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. R. J. Ellis, W. Toperoff, F. Vaida et al., “Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial,” Neuropsychopharmacology, vol. 34, no. 3, pp. 672–680, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. J. S. Berman, C. Symonds, and R. Birch, “Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial,” Pain, vol. 112, no. 3, pp. 299–306, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. M. A. Ware, T. Wang, S. Shapiro et al., “Smoked cannabis for chronic neuropathic pain: a randomized controlled trial,” Canadian Medical Association Journal, vol. 182, no. 14, pp. E694–E701, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. E. T. Varro, R. B. Lynn, and E. R. James, Pharmacognosy, Lea & Fabigen, Philadelphia, Pa, USA, 9th edition, 1988.
  84. G. B. Norman and W. Max, Herbal Drugs and Phytopharmaceuticals, CRC Press, London, UK, 2nd edition, 2001.
  85. A. N. A. Abad, M. H. K. Nouri, A. Gharjanie, and F. Tavakoli, “Effect of Matricaria chamomilla hydroalcoholic extract on Cisplatin-induced neuropathy in mice,” Chinese Journal of Natural Medicines, vol. 9, no. 2, pp. 126–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. G. Oztürk, O. Anlar, ErdoğanE, M. Kösem, H. Ozbek, and A. Türker, “The effect of Ginkgo extract EGb761 in Cisplatin-induced peripheral neuropathy in mice,” Toxicology and Applied Pharmacology, vol. 196, no. 1, pp. 169–175, 2004. View at Publisher · View at Google Scholar
  87. J. Marshall, A. Zakari, J. J. Hwang, V. Papadopoulos, A. Rosenberg, and C. Silver, “Ginkgo biloba, (GB) extract as a neuroprotective agent in oxaliplatin (Ox)-induced neuropathy. American Society of Clinical Oncologists Annual Meeting Proceedings,” Journal of Clinical Oncology, vol. 22, supplement 14, abstract 3670, 2004. View at Google Scholar
  88. A. N. A. Abad, M. H. K. Nouri, and F. Tavakkoli, “Effect of Salvia officinalis hydroalcoholic extract on vincristine-induced neuropathy in mice,” Chinese Journal of Natural Medicines, vol. 9, no. 5, pp. 354–358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. J. W. Park, J. H. Jeon, J. W. Yoon et al., “Effects of sweet bee venom pharmacopuncture treatment for chemotherapy-induced peripheral neuropathy: a case series,” Integrative Cancer Therapies, vol. 11, no. 2, pp. 166–171, 2011. View at Publisher · View at Google Scholar
  90. J. Yoon, J. H. Jeon, Y. W. Lee et al., “Sweet bee venom pharmacopuncture for chemotherapy-induced peripheral neuropathy,” Journal of Acupuncture and Meridian Studies, vol. 5, no. 4, pp. 156–165, 2012. View at Publisher · View at Google Scholar
  91. F. Xu, S. Xu, L. Wang et al., “Antinociceptive efficacy of verticinone in murine models of inflammatory pain and paclitaxel induced neuropathic pain,” Biological and Pharmaceutical Bulletin, vol. 34, no. 9, pp. 1377–1382, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. Y. Y. Sun, Y. J. Jia, M. N. Huang, and J. Chen, “Buyang huanwu decoction in prevention of peripheral neuropathy after chemotherapy: a clinical observation,” Guangming Journal of Chinese Medicine, vol. 23, no. 7, pp. 958–959, 2008. View at Google Scholar
  93. J. H. Deng and S. L. Zou, “Observation on TCM treatment of 32 cases of chemotherapy-induced peripheral neuropathy,” Journal of Practical Traditional Chinese Internal Medicine, vol. 21, no. 2, 2007. View at Google Scholar
  94. L. Pan, H. Gao, and X. R. Xing, “Combined application of traditional Chinese medicine prevention of taxol chemotherapy-induced peripheral neuropathy: a clinical observation,” Neimenggu Zhong Yi Yao, vol. 3, p. 28, 2012. View at Google Scholar
  95. L. Sima and L. Pan, “Influence of Chinese herb on chemotherapy-induced peripheral neuropathy,” Annals of Oncology, vol. 20, supplement 3, pp. iii45–iii46, 2009. View at Publisher · View at Google Scholar
  96. K. Hashimoto, Y. Sakuma, and J. Kotani, “Histological study of a paclitaxel-induced peripheral neuropathy model treated with goshajnkigan,” The Journal of Osaka Dental University, vol. 38, no. 2, pp. 109–112, 2004. View at Google Scholar
  97. K. Hashimoto, Y. Sakuma, and J. Kotani, “Goshajinkigan improves paclitaxel-induced peripheral neuropathy in rats,” The Journal of Osaka Dental University, vol. 40, no. 1, pp. 47–52, 2006. View at Google Scholar
  98. S. Ushio, N. Egashira, H. Sada et al., “Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents,” European Journal of Cancer, vol. 48, no. 9, pp. 1407–1413, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. Y. Shindo, K. Tenma, H. Imano, M. Hibino, K. Yoshino, and M. Nakamura, “Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan,” Gan to Kagaku Ryoho, vol. 35, no. 5, pp. 863–865, 2008. View at Google Scholar · View at Scopus
  100. M. Nishioka, M. Shimada, N. Kurita et al., “The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen,” International Journal of Clinical Oncology, vol. 16, no. 4, pp. 322–327, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. T. Kono, N. Mamiya, N. Chisato et al., “Efficacy of Goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 418481, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. T. Yamamoto, T. Murai, M. Ueda et al., “Clinical features of paclitaxel-induced peripheral neuropathy and role of Gosya-jinki-gan,” Gan to Kagaku Ryoho, vol. 36, no. 1, pp. 89–92, 2009 (Japanese). View at Google Scholar · View at Scopus
  103. H. Kaku, S. Kumagai, H. Onoue et al., “Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: a multicenter collaborative study,” Experimental and Therapeutic Medicine, vol. 3, no. 1, pp. 60–65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. T. Yamada, H. Kan, S. Matsumoto et al., “Reduction in oxaliplatin-related neurotoxicity by the administration of Keishikajutsubuto (TJ-18)and powdered processed aconite root,” Gan to Kagaku Ryoho, vol. 39, no. 11, pp. 1687–1691, 2012 (Japanese). View at Google Scholar
  105. T. Tatsumi, D. Kishi, and T. Kogure, “The efficacy of ogikeishigomotsuto on chronic cumulative sensory neuropathy induced by Oxaliplatin—case report and literature view,” Journal of Traditional Medicines, vol. 26, no. 3, pp. 136–140, 2009. View at Google Scholar
  106. T. Hidaka, T. Shima, K. Nagira et al., “Herbal medicine Shakuyaku-kanzo-to reduces paclitaxel-induced painful peripheral neuropathy in mice,” European Journal of Pain, vol. 13, no. 1, pp. 22–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. K. Fujii, S. Okamoto, K. Saitoh et al., “The efficacy of Shakuyaku-Kanzo-to for peripheral nerve dysfunction in paclitaxel combination chemotherapy for epithelial ovarian carcinoma,” Gan to Kagaku Ryoho, vol. 31, no. 10, pp. 1537–1540, 2004. View at Google Scholar · View at Scopus
  108. A. Hosokawa, K. Ogawa, T. Ando et al., “Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study,” Anticancer Research, vol. 32, no. 7, pp. 2545–2550, 2012. View at Google Scholar
  109. F. V. Defeudis, “Bilobalide and neuroprotection,” Pharmacological Research, vol. 46, no. 6, pp. 565–568, 2002. View at Publisher · View at Google Scholar · View at Scopus
  110. F. V. DeFeudis, V. Papadopoulos, and K. Drieu, “Ginkgo biloba extracts and cancer: a research area in its infancy,” Fundamental and Clinical Pharmacology, vol. 17, no. 4, pp. 405–417, 2003. View at Publisher · View at Google Scholar · View at Scopus
  111. B. Ahlemeyer and J. Krieglstein, “Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease,” Pharmacopsychiatry, vol. 36, supplement 1, pp. 8–14, 2003. View at Google Scholar · View at Scopus
  112. H. J. P. Dorman, S. G. Deans, R. C. Noble et al., “Evaluation in vitro of plant essential oils as natural antioxidants,” Journal of Essential Oil Research, vol. 7, no. 6, pp. 645–651, 1995. View at Publisher · View at Google Scholar · View at Scopus
  113. J. Hohmann, I. Zupkó, D. Rédei et al., “Protective effects of the aerial parts of Salvia officinalis, Melissa officinalis and Lavandula angustifolia and their constituents against enzyme-dependent and enzyme-independent lipid peroxidation,” Planta Medica, vol. 65, no. 6, pp. 576–578, 1999. View at Publisher · View at Google Scholar · View at Scopus
  114. D. Malencić, O. Gasic, M. Popović, and P. Boza, “Screening for antioxidant properties of Salvia reflexa hornem,” Phytotherapy Research, vol. 14, no. 7, pp. 546–548, 2000. View at Google Scholar
  115. I. Zupkó, J. Hohmann, D. Rédei, G. Falkay, G. Janicsák, and I. Máthé, “Antioxidant activity of leaves of Salvia species in enzyme-dependent and enzyme-independent systems of lipid peroxidation and their phenolic constituents,” Planta Medica, vol. 67, no. 4, pp. 366–368, 2001. View at Publisher · View at Google Scholar · View at Scopus
  116. C. N. Wang, C. W. Chi, Y. L. Lin, C. F. Chen, and Y. J. Shiao, “The neuroprotective effects of phytoestrogens on amyloid β protein-induced toxicity are mediated by abrogating the activation of caspase cascade in rat cortical neurons,” The Journal of Biological Chemistry, vol. 276, no. 7, pp. 5287–5295, 2001. View at Publisher · View at Google Scholar · View at Scopus
  117. M. J. Howes, N. S. Perry, and P. J. Houghton, “Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders,” Phytotherapy Research, vol. 17, no. 1, pp. 1–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. Y. A. Maklad, E. A. Aboutabl, M. M. El-Sherei, and K. M. Meselhy, “Bioactivity studies of Salvia transsylvanica (Schur ex Griseb) grown in Egypt,” Phytotherapy Research, vol. 13, no. 2, pp. 147–150, 1999. View at Google Scholar
  119. M. R. A. Rodrigues, L. K. S. Kanazawa, T. L. M. D. Neves et al., “Antinociceptive and anti-inflammatory potential of extract and isolated compounds from the leaves of Salvia officinalis in mice,” Journal of Ethnopharmacology, vol. 139, no. 2, pp. 519–526, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. S. Y. Yoon, D. H. Roh, Y. B. Kwon et al., “Acupoint stimulation with diluted bee venom (apipuncture) potentiates the analgesic effect of intrathecal clonidine in the rodent formalin test and in a neuropathic pain model,” The Journal of Pain, vol. 10, no. 3, pp. 253–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. S. Y. Kang, D. H. Roh, S. Y. Yoon et al., “Repetitive treatment with diluted bee venom reduces neuropathic pain via potentiation of locus coeruleus noradrenergic neuronal activity and modulation of spinal NR1 phosphorylation in rats,” The Journal of Pain, vol. 13, no. 2, pp. 155–166, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. Q. R. Wang, Yi Lin Gai Cuo: Correcting the Errors in the Forest of Medicine, Blue Poppy Press, Boulder, Colo, USA, 2007.
  123. Y. Qian, Xiaoer Yaozheng Zhijue. With coments by X. Z. Yan, J. S. Guo. People's Medical Publishing House. 2006.
  124. Z. J. Zhang, On Cold Damage (Shang Han Lun), Translation & Commentaries by Y. Feng, N. Wiseman, C. Mitchell and Y. Feng, Blue Poppy Press, Boulder, Colo, USA, 2000.
  125. Y. H. Yan, Jisheng fang, first published in 1253. Reprint Shangwu Yin Shu Guan, Taibei, Taiwan, 1975.
  126. Japan Society for Oriental Medicine, Introduction to Kampo. Japanese Traditional Medicine, Elsevier, Tokio, Japan, 2005.
  127. Y. Niwa and Y. Miyachi, “Antioxidant action of natural health products and Chinese herbs,” Inflammation, vol. 10, no. 1, pp. 79–91, 1986. View at Google Scholar · View at Scopus
  128. B. J. Kim, J. H. Kim, H. P. Kim, and M. Y. Heo, “Biological screening of 100 plant extracts for cosmetic use (II): anti-oxidative activity and free radical scavenging activity,” International Journal of Cosmetic Science, vol. 19, no. 6, pp. 299–307, 1997. View at Publisher · View at Google Scholar · View at Scopus
  129. M. Tawata, A. Kurihara, K. Nitta, E. Iwase, N. Gan, and T. Onaya, “The effects of Goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy,” Diabetes Research and Clinical Practice, vol. 26, no. 2, pp. 121–128, 1994. View at Publisher · View at Google Scholar · View at Scopus
  130. T. Kono, H. Mishima, M. Shimada, S. Morita, and J. Sakamoto, “Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study),” Japanese Journal of Clinical Oncology, vol. 39, no. 12, pp. 847–849, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. M. Nakanishi, J. Arimitsu, M. Kageyama et al., “Efficacy of traditional Japanese herbal medicines-Keishikajutsubuto (TJ-18) and Bushi-matsu (TJ-3022)-against postherpetic neuralgia aggravated by self-reported cold stimulation: a case series,” The Journal of Alternative and Complementary Medicine, vol. 18, no. 7, pp. 686–692, 2012. View at Publisher · View at Google Scholar
  132. J. Z. Zhang, Gui Yao Lue (Essential Prescriptions from the Golden Chamber), Translated by Nigel Wiseman, Paradigm Publications, Taos, NM, USA, 2013.
  133. H. Hikiami, K. Yagi, S. Nakata et al., “Two cases of numbness and pain of neuropathy due to ANCA-associated vasculitis successfully treated with ogikeishigomotsuto,” Kampo Medicine, vol. 58, no. 3, pp. 495–501, 2007. View at Publisher · View at Google Scholar
  134. H. Fujiwara, T. Urabe, K. Ueda et al., “Prevention of arthralgia and myalgia from paclitaxel and carboplatin combination chemotherapy with Shakuyaku-kanzo-to,” Gan to Kagaku Ryoho, vol. 27, no. 7, pp. 1061–1064, 2000. View at Google Scholar · View at Scopus
  135. K. Hasegawa, Y. Mizutani, H. Kuramoto et al., “The effect of L-Glutamine and Shakuyaku-Kanzo-to for paclitaxel-induced myalgia/arthralgia,” Gan to Kagaku Ryoho, vol. 29, no. 4, pp. 569–574, 2002. View at Google Scholar · View at Scopus
  136. K. Yamamoto, H. Hoshiai, and K. Noda, “Effects of Shakuyaku-kanzo-to on muscle pain from combination chemotherapy with paclitaxel and carboplatin,” Gynecologic Oncology, vol. 81, no. 2, pp. 333–334, 2001. View at Publisher · View at Google Scholar · View at Scopus
  137. S. Derry, A. Sven-Rice, P. Cole et al., “Topical capsaicin (high concentration) for chronic neuropathic pain in adults,” Cochrane Database of Systematic Reviews, vol. 2, Article ID CD007393, 2013. View at Publisher · View at Google Scholar · View at Scopus
  138. K. Shibata, T. Sugawara, K. Fujishita et al., “The astrocyte-targeted therapy by Bushi for the neuropathic pain in mice,” PLoS ONE, vol. 6, no. 8, Article ID e23510, 2011. View at Publisher · View at Google Scholar
  139. H. Xu, H. Arita, M. Hayashida, L. Zhang, H. Sekiyama, and K. Hanaoka, “Pain-relieving effects of processed Aconiti tuber in CCI-neuropathic rats,” Journal of Ethnopharmacology, vol. 103, no. 3, pp. 392–397, 2006. View at Publisher · View at Google Scholar · View at Scopus
  140. S. Tatsumi, T. Mabuchi, T. Abe, L. Xu, T. Minami, and S. Ito, “Analgesic effect of extracts of Chinese medicinal herbs Moutan cortex and Coicis semen on neuropathic pain in mice,” Neuroscience Letters, vol. 370, no. 2-3, pp. 130–134, 2004. View at Publisher · View at Google Scholar · View at Scopus
  141. M. Kanter, “Effects of Nigella sativa and its major constituent, thymoquinone on sciatic nerves in experimental diabetic neuropathy,” Neurochemical Research, vol. 33, no. 1, pp. 87–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  142. A. Muthuraman, V. Diwan, A. S. Jaggi, N. Singh, and D. Singh, “Ameliorative effects of Ocimum sanctum in sciatic nerve transection-induced neuropathy in rats,” Journal of Ethnopharmacology, vol. 120, no. 1, pp. 56–62, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. T. Baluchnejadmojarad, M. Roghani, and F. Roghani-Dehkordi, “Antinociceptive effect of Teucrium polium leaf extract in the diabetic rat formalin test,” Journal of Ethnopharmacology, vol. 97, no. 2, pp. 207–210, 2005. View at Publisher · View at Google Scholar · View at Scopus
  144. C. A. L. Kassuya, A. A. Silvestre, V. L. G. Rehder, and J. B. Calixto, “Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain,” European Journal of Pharmacology, vol. 478, no. 2-3, pp. 145–153, 2003. View at Publisher · View at Google Scholar · View at Scopus
  145. R. B. Pandhare, B. Sangameswaran, P. B. Mohite et al., “Attenuating effect of Sesbania sesban (L) Merr. extract on neuropathic pain in streptozotocin-induced diabetic rats: an evidence of neuroprotective effects,” Phytopharmacology, vol. 2, no. 1, pp. 190–201, 2012. View at Google Scholar
  146. D. M. Eisenberg, E. S. J. Harris, B. A. Littlefield et al., “Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation-rationale, methods and preliminary results from a Sino-American collaboration,” Fitoterapia, vol. 82, no. 1, pp. 17–33, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. Q. Luo, Y. Cai, J. Yan, M. Sun, and H. Corke, “Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum,” Life Sciences, vol. 76, no. 2, pp. 137–149, 2004. View at Publisher · View at Google Scholar · View at Scopus
  148. Y. Suzuki, K. Goto, A. Ishige, Y. Komatsu, and J. Kamei, “Antinociceptive effect of Gosha-jinki-gan, a Kampo medicine, in streptozotocin-induced diabetic mice,” The Japanese Journal of Pharmacology, vol. 79, no. 2, pp. 169–175, 1999. View at Publisher · View at Google Scholar · View at Scopus
  149. I. Raskin and C. Ripoll, “Can an apple a day keep the doctor away?” Current Pharmaceutical Design, vol. 10, no. 27, pp. 3419–3429, 2004. View at Publisher · View at Google Scholar · View at Scopus
  150. B. M. Schmidt, D. M. Ribnicky, P. E. Lipsky, and I. Raskin, “Revisiting the ancient concept of botanical therapeutics,” Nature Chemical Biology, vol. 3, no. 7, pp. 360–366, 2007. View at Publisher · View at Google Scholar · View at Scopus
  151. H. Shu, H. Arita, M. Hayashida, H. Sekiyama, and K. Hanaoka, “Effects of processed Aconiti tuber and its ingredient alkaloids on the development of antinociceptive tolerance to morphine,” Journal of Ethnopharmacology, vol. 103, no. 3, pp. 398–405, 2006. View at Publisher · View at Google Scholar · View at Scopus
  152. M. Murayama, T. Mori, H. Bando, and T. Amiya, “Studies on the constituents of Aconitum species. IX. The pharmacological properties of pyro-type aconitine alkaloids, components of processed aconite powder ‘kako-bushi-matsu’: analgesic, antiinflammatory and acute toxic activities,” Journal of Ethnopharmacology, vol. 35, no. 2, pp. 159–164, 1991. View at Google Scholar · View at Scopus
  153. K. Yamada, E. Suzuki, T. Nakaki, S. Watanabe, and S. Kanba, “Aconiti tuber increases plasma nitrite and nitrate levels in humans,” Journal of Ethnopharmacology, vol. 96, no. 1-2, pp. 165–169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  154. M. Mitamura, K. Boussery, S. Horie, T. Murayama, and J. van de Voorde, “Vasorelaxing effect of mesaconitine, an alkaloid from Aconitum japonicum, on rat small gastric artery: possible involvement of endothelium-derived hyperpolarizing factor,” The Japanese Journal of Pharmacology, vol. 89, no. 4, pp. 380–387, 2002. View at Publisher · View at Google Scholar · View at Scopus
  155. Y. Suzuki, K. Goto, A. Ishige, Y. Komatsu, and J. Kamei, “Effects of Gosha-jinki-gan, a Kampo medicine, on peripheral tissue blood flow in streptozotocin-induced diabetic rats,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 20, no. 4, pp. 321–328, 1998. View at Publisher · View at Google Scholar · View at Scopus
  156. Y. Cui, Z. Yan, S. Hou, and Z. Chang, “Effect of radix Rehmanniae preparata on the expression of c-fos and NGF in hippocampi and learning and memory in rats with damaged thalamic arcuate nucleus,” Zhong Yao Cai, vol. 27, no. 8, pp. 589–592, 2004. View at Google Scholar · View at Scopus
  157. J. G. Choi, M. Moon, H. U. Jeong, M. C. Kim, S. Y. Kim, and M. S. Oh, “Cistanches Herba enhances learning and memory by inducing nerve growth factor,” Behavioural Brain Research, vol. 216, no. 2, pp. 652–658, 2011. View at Publisher · View at Google Scholar · View at Scopus
  158. C. Matsumoto, T. Kojima, K. Ogawa et al., “A proteomic approach for the diagnosis of ‘Oketsu’ (blood stasis), a pathophysiologic concept of Japanese traditional (Kampo) medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 4, pp. 463–474, 2008. View at Publisher · View at Google Scholar · View at Scopus
  159. C. R. Li, Z. Zhou, D. Zhu, Y. N. Sun, J. M. Dai, and S. Q. Wang, “Protective effect of paeoniflorin on irradiation-induced cell damage involved in modulation of reactive oxygen species and the mitogen-activated protein kinases,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 2, pp. 426–438, 2007. View at Publisher · View at Google Scholar · View at Scopus
  160. Y. Zhu, S. Dang, and Z. Hua, “Advanced achievements about neuroprotective mechanisms of paeoniflorin,” Zhongguo Zhong Yao Za Zhi, vol. 35, no. 11, pp. 1490–1493, 2010. View at Publisher · View at Google Scholar · View at Scopus
  161. H. Chunnian, P. Yong, F. Yuxiong, P. Bing, W. Zhe, and X. Peigen, “Quick comparison of Radix Paeonia Alba, Radix Paeonia Rubra, and Cortex Moutan by high performance liquid chromatography coupled with monolithic columns and their chemical pattern recognition,” Pharmacognosy Magazine, vol. 8, no. 31, pp. 237–243, 2012. View at Publisher · View at Google Scholar
  162. M. C. Lu, C. H. Yao, S. H. Wang, Y. L. Lai, C. C. Tsai, and Y. S. Chen, “Effect of Astragalus membranaceus in rats on peripheral nerve regeneration: in vitro and in vivo studies,” Journal of Trauma, vol. 68, no. 2, pp. 434–440, 2010. View at Publisher · View at Google Scholar · View at Scopus
  163. J. Yu, Y. Zhang, S. Sun et al., “Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats,” Canadian Journal of Physiology and Pharmacology, vol. 84, no. 6, pp. 579–587, 2006. View at Publisher · View at Google Scholar · View at Scopus
  164. N. Y. Tang, C. H. Liu, S. Y. Su et al., “Uncaria rhynchophylla (Miq) Jack plays a role in neuronal protection in kainic acid-treated rats,” American Journal of Chinese Medicine, vol. 38, no. 2, pp. 251–263, 2010. View at Publisher · View at Google Scholar · View at Scopus
  165. H. Y. Zhang, Y. H. Liu, H. Q. Wang, J. H. Xu, and H. T. Hu, “Puerarin protects PC12 cells against β-amyloid-induced cell injury,” Cell Biology International, vol. 32, no. 10, pp. 1230–1237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  166. H. Zhang, Y. Liu, M. Lao, Z. Ma, and X. Yi, “Puerarin protects Alzheimer's disease neuronal cybrids from oxidant-stress induced apoptosis by inhibiting pro-death signaling pathways,” Experimental Gerontology, vol. 46, no. 1, pp. 30–37, 2011. View at Publisher · View at Google Scholar · View at Scopus
  167. D. Sha, L. Li, L. Ye, R. Liu, and Y. Xu, “Icariin inhibits neurotoxicity of β-amyloid by upregulating cocaine-regulated and amphetamine-regulated transcripts,” Neuroreport, vol. 20, no. 17, pp. 1564–1567, 2009. View at Publisher · View at Google Scholar · View at Scopus
  168. Y. S. Ho, M. S. Yu, S. Y. Yik, K. F. So, W. H. Yuen, and R. C. Chang, “Polysaccharides from wolfberry antagonizes glutamate excitotoxicity in rat cortical neurons,” Cellular and Molecular Neurobiology, vol. 29, no. 8, pp. 1233–1244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  169. Y. H. Wang and G. H. Du, “Ginsenoside Rg1 inhibits β-secretase activity in vitro and protects against Aβ-induced cytotoxicity in PC12 cells,” Journal of Asian Natural Products Research, vol. 11, no. 7, pp. 604–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  170. C. P. Hoi, Y. P. Ho, L. Baum, and A. H. L. Chow, “Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta-amyloid-induced toxicity in PC12 cells,” Phytotherapy Research, vol. 24, no. 10, pp. 1538–1542, 2010. View at Publisher · View at Google Scholar · View at Scopus
  171. H. W. Zhao and X. Y. Li, “Ginkgolide A, B, and huperzine A inhibit nitric oxide-induced neurotoxicity,” International Immunopharmacology, vol. 2, no. 11, pp. 1551–1556, 2002. View at Publisher · View at Google Scholar · View at Scopus
  172. E. H. Kim, M. H. Jang, M. C. Shin, M. S. Shin, and C. J. Kim, “Protective effect of aqueous extract of Ginseng radix against 1-methyl-4-phenylpyridinium-induced apoptosis in PC12 cells,” Biological and Pharmaceutical Bulletin, vol. 26, no. 12, pp. 1668–1673, 2003. View at Publisher · View at Google Scholar · View at Scopus
  173. R. C. Choi, Z. Jiang, H. Q. Xie et al., “Anti-oxidative effects of the biennial flower of Panax notoginseng against H2O2-induced cytotoxicity in cultured PC12 cells,” Chinese Medicine, vol. 5, article 38, 2010. View at Publisher · View at Google Scholar · View at Scopus
  174. X. Li, K. Matsumoto, Y. Murakami, Y. Tezuka, Y. Wu, and S. Kadota, “Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice,” Pharmacology Biochemistry and Behavior, vol. 82, no. 2, pp. 345–352, 2005. View at Publisher · View at Google Scholar · View at Scopus
  175. W. Wang and D. Q. Wang, “Progress of study on brain protective effect and mechanism of Polygonum multiflorum,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 25, no. 10, pp. 955–959, 2005. View at Google Scholar · View at Scopus
  176. X. Li, Y. Li, J. Chen et al., “Tetrahydroxystilbene glucoside attenuates MPP+-induced apoptosis in PC12 cells by inhibiting ROS generation and modulating JNK activation,” Neuroscience Letters, vol. 483, no. 1, pp. 1–5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  177. K. Faust, S. Gehrke, Y. Yang, L. Yang, M. F. Beal, and B. Lu, “Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease,” BMC Neuroscience, vol. 10, article 109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  178. L. L. Tian, X. J. Wang, Y. N. Sun et al., “Salvianolic acid B, an antioxidant from Salvia miltiorrhiza, prevents 6-hydroxydopamine induced apoptosis in SH-SY5Y cells,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 3, pp. 409–422, 2008. View at Publisher · View at Google Scholar · View at Scopus
  179. S. X. Wang, L. M. Hu, X. M. Gao, H. Guo, and G. W. Fan, “Anti-inflammatory activity of salvianolic acid B in microglia contributes to its neuroprotective effect,” Neurochemical Research, vol. 35, no. 7, pp. 1029–1037, 2010. View at Publisher · View at Google Scholar · View at Scopus
  180. W. J. Xia, M. Yang, T. F. Fok et al., “Partial neuroprotective effect of pretreatment with tanshinone IIA on neonatal hypoxia-ischemia brain damage,” Pediatric Research, vol. 58, no. 4, pp. 784–790, 2005. View at Publisher · View at Google Scholar · View at Scopus
  181. E. J. Shin, J. H. Bach, T. T. L. Nguyen et al., “Gastrodia elata bl attenuates methamphetamine-induced dopaminergic toxicity via inhibiting oxidative burdens,” Current Neuropharmacology, vol. 9, no. 1, pp. 118–121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  182. C. L. Hsieh, C. L. Chen, N. Y. Tang et al., “Gastrodia elata BL mediates the suppression of nnos and microglia activation to protect against neuronal damage in kainic acid-treated rats,” American Journal of Chinese Medicine, vol. 33, no. 4, pp. 599–611, 2005. View at Publisher · View at Google Scholar · View at Scopus
  183. S. Y. Li, Y. H. Jia, W. G. Sun et al., “Stabilization of mitochondrial function by tetramethylpyrazine protects against kainate-induced oxidative lesions in the rat hippocampus,” Free Radical Biology and Medicine, vol. 48, no. 4, pp. 597–608, 2010. View at Publisher · View at Google Scholar · View at Scopus
  184. L. H. Fan, K. Z. Wang, B. Cheng, C. S. Wang, and X. Q. Dang, “Anti-apoptotic and neuroprotective effects of Tetramethylpyrazine following spinal cord ischemia in rabbits,” BMC Neuroscience, vol. 7, article 48, 2006. View at Publisher · View at Google Scholar · View at Scopus
  185. J. H. Park, H. J. Lee, S. B. Koh, J. Y. Ban, and Y. H. Seong, “Protection of NMDA-induced neuronal cell damage by methanol extract of Zizyphi Spinosi Semen in cultured rat cerebellar granule cells,” Journal of Ethnopharmacology, vol. 95, no. 1, pp. 39–45, 2004. View at Publisher · View at Google Scholar · View at Scopus
  186. F. Q. Li, T. Wang, Z. Pei, B. Liu, and J. S. Hong, “Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons,” Journal of Neural Transmission, vol. 112, no. 3, pp. 331–347, 2005. View at Publisher · View at Google Scholar · View at Scopus
  187. C. Ma, W. Wang, Y. Y. Chen, R. N. Liu, R. F. Wang, and L. J. Du, “Neuroprotective and antioxidant activity of compounds from the aerial parts of Dioscorea opposita,” Journal of Natural Products, vol. 68, no. 8, pp. 1259–1261, 2005. View at Publisher · View at Google Scholar · View at Scopus
  188. B. Xue, J. Jiao, L. Zhang et al., “Triptolide upregulates NGF synthesis in rat astrocyte cultures,” Neurochemical Research, vol. 32, no. 7, pp. 1113–1119, 2007. View at Publisher · View at Google Scholar · View at Scopus
  189. H. Y. Zhang and X. C. Tang, “Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease,” Trends in Pharmacological Sciences, vol. 27, no. 12, pp. 619–625, 2006. View at Publisher · View at Google Scholar · View at Scopus
  190. M. S. Rafii, S. Walsh, J. T. Little et al., “A phase II trial of huperzine A in mild to moderate Alzheimer disease,” Neurology, vol. 76, no. 16, pp. 1389–1394, 2011. View at Publisher · View at Google Scholar · View at Scopus
  191. L. Gao, L. Xiang, Y. Luo, G. Wang, J. Li, and J. Qi, “Gentisides C-K: nine new neuritogenic compounds from the traditional Chinese medicine Gentiana rigescens Franch,” Bioorganic and Medicinal Chemistry, vol. 18, no. 19, pp. 6995–7000, 2010. View at Publisher · View at Google Scholar · View at Scopus
  192. Y. Cui, Z. Yan, S. Hou, and Z. Chang, “Effect of radix Rehmanniae preparata on the expression of c-fos and NGF in hippocampi and learning and memory in rats with damaged thalamic arcuate nucleus,” Zhong Yao Cai, vol. 27, no. 8, pp. 589–592, 2004. View at Google Scholar · View at Scopus
  193. Y. Zhu, S. Dang, and Z. Hua, “Advanced achievements about neuroprotective mechanisms of paeoniflorin,” Zhongguo Zhong Yao Za Zhi, vol. 35, no. 11, pp. 1490–1493, 2010. View at Publisher · View at Google Scholar · View at Scopus